Literature DB >> 2188739

Growth inhibition of Candida albicans by interleukin-2-induced lymph node cells.

D W Beno1, H L Mathews.   

Abstract

Previous reports have demonstrated natural killer cells (NK) to exert growth inhibitory effects against certain fungi, but not against Candida albicans. In this investigation, interleukin-2 (IL-2)-induced lymph node cells with phenotypic and functional characteristics of NK were shown to inhibit the growth of C. albicans. Growth inhibition was evaluated by both the release of 51Cr by the fungus and the inhibition of microcolony growth of the fungus on Sabouraud's dextrose agar. Lymphoid cells derived from C57Bl/6 mice and immediately assessed for hyphal growth inhibition showed little or no activity. However, significant hyphal growth inhibition was produced by lymph node cells cultured with recombinant IL-2. Growth inhibitory activity was dependent upon the concentration of IL-2 and was mediated by nonadherent lymphocytes which lysed an NK-susceptible and to a lesser extent an NK-resistant cell line. Treatment of the IL-2-induced cells with anti-asialo GM1 but not anti-Thy-1 and complement abrogated growth inhibition of C. albicans. These results suggest that IL-2-induced lymph node cells with functional and phenotypic characteristics similar to those of activated NK, mediate in vitro growth inhibition of the hyphal form of C. albicans.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2188739     DOI: 10.1016/0008-8749(90)90009-g

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

1.  Vaginal and oral epithelial cell anti-Candida activity.

Authors:  Fatema Nomanbhoy; Chad Steele; Junko Yano; Paul L Fidel
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  Noninhibitory binding of human interleukin-2-activated natural killer cells to the germ tube forms of Candida albicans.

Authors:  G Arancia; A Molinari; P Crateri; A Stringaro; C Ramoni; M L Dupuis; M J Gomez; A Torosantucci; A Cassone
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

3.  Growth inhibition of Candida albicans by interleukin-2-activated splenocytes.

Authors:  D W Beno; H L Mathews
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

4.  Early differential molecular response of a macrophage cell line to yeast and hyphal forms of Candida albicans.

Authors:  E Blasi; L Pitzurra; M Puliti; L Lanfrancone; F Bistoni
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

5.  Differential susceptibility of yeast and hyphal forms of Candida albicans to macrophage-derived nitrogen-containing compounds.

Authors:  E Blasi; L Pitzurra; M Puliti; A R Chimienti; R Mazzolla; R Barluzzi; F Bistoni
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

6.  Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans.

Authors:  S M Levitz
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

Review 7.  Production and function of cytokines in natural and acquired immunity to Candida albicans infection.

Authors:  R B Ashman; J M Papadimitriou
Journal:  Microbiol Rev       Date:  1995-12

8.  Immune cell-mediated protection against vaginal candidiasis: evidence for a major role of vaginal CD4(+) T cells and possible participation of other local lymphocyte effectors.

Authors:  Giorgio Santoni; Maria Boccanera; Daniela Adriani; Roberta Lucciarini; Consuelo Amantini; Stefania Morrone; Antonio Cassone; Flavia De Bernardis
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

9.  gamma Interferon gene expression and release in human lymphocytes directly activated by Cryptococcus neoformans and Candida albicans.

Authors:  S M Levitz; E A North
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

10.  Effect of abrogation of natural killer cell activity on the course of candidiasis induced by intraperitoneal administration and gastrointestinal candidiasis in mice with severe combined immunodeficiency.

Authors:  R A Greenfield; V L Abrams; D L Crawford; T L Kuhls
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.